Insulet Launches Pivotal Study for Fully Closed-Loop Insulin System in Type 2 Diabetes
Event summary
- Insulet Corporation has enrolled the first participant in the EVOLVE pivotal study for its fully closed-loop automated insulin delivery (AID) system for type 2 diabetes (T2D).
- The multi-center randomized control trial aims to enroll up to 350 adults across 40 U.S. sites, with IDE approval received from the FDA in March 2026.
- Insulet's FCL AID system is designed to eliminate user interactions for bolusing and mealtime announcements, reducing burden for T2D patients and healthcare professionals.
- The company plans to submit a 510(k) filing to the FDA in 2027 and launch the FCL AID system for T2D in 2028.
The big picture
Insulet's EVOLVE study represents a strategic push to dominate the automated insulin delivery market for type 2 diabetes, an area with significant unmet needs. The company aims to streamline onboarding and reduce workload for healthcare professionals, addressing a critical bottleneck in primary care settings where 70% of T2D patients are managed. Success could position Insulet as a leader in diabetes management technology, but it faces challenges in scaling adoption and navigating regulatory hurdles.
What we're watching
- Regulatory Milestones
- The pace at which Insulet secures FDA approval for its FCL AID system will determine its market entry timeline and competitive positioning.
- Adoption Barriers
- Whether Insulet can significantly expand AID adoption beyond the current 5% penetration among the 5.5 million T2D patients requiring insulin.
- Clinical Efficacy
- How the EVOLVE study results compare to previous feasibility studies, particularly the 24% time in range improvement observed in earlier trials.
Related topics